<html><head><style>div {border : red solid 0.5px}</style><style>span {border : blue dotted 0.5px}</style></head><body><div left="161.83" right="233.86" top="754.79"><span x0="161.83" y0="754.79" x1="233.86" style="x0: 161.83; x1: 168.68; y0: 754.79; y1: 764.79; width: 6.85; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Black;">CAPACITIES &amp; FUNCTIONS NATIONAL STANDARDSREGIONAL/GLOBAL STANDARDS</span></div><div left="142.8" right="240.1" top="722.11"><span x0="142.8" y0="722.11" x1="240.1" style="x0: 142.8; x1: 150.21; y0: 722.11; y1: 732.11; width: 7.41; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Roman;">Data and information sharingAll countries have made commitments to sharing genetic data, clinical specimens, and/or isolated specimens (biological materials) in both emergency and nonemergency contexts.</span></div><div left="414.93" right="518.18" top="722.11"><span x0="414.93" y0="722.11" x1="518.18" style="x0: 414.93; x1: 420.67; y0: 722.11; y1: 732.11; width: 5.74; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Roman;">There is a data sharing platform with open centralized access to data and rapid pathogen sharing.</span></div><div left="414.93" right="547.16" top="655.61"><span x0="414.93" y0="655.61" x1="547.16" style="x0: 414.93; x1: 420.67; y0: 655.61; y1: 665.61; width: 5.74; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Roman;">There is a global platform for sharing data and information integrated across sectors to support decision-making and resource allocation.</span></div><div left="142.8" right="227.36" top="582.94"><span x0="142.8" y0="582.94" x1="227.36" style="x0: 142.8; x1: 150.58; y0: 582.94; y1: 592.94; width: 7.78; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Roman;">Norms, standards, evidence-based policy, technical support</span></div><div left="414.93" right="543.91" top="582.94"><span x0="414.93" y0="582.94" x1="543.91" style="x0: 414.93; x1: 420.67; y0: 582.94; y1: 592.94; width: 5.74; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Roman;">There is a global mechanism to develop, review, and disseminate norms, standards, evidence-based policy and provide technical support to countries. </span></div><div left="142.8" right="228.92" top="496.97"><span x0="142.8" y0="496.97" x1="228.92" style="x0: 142.8; x1: 148.91; y0: 496.97; y1: 506.97; width: 6.11; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Roman;">R&amp;D on future and emerging infectious diseases</span></div><div left="261.86" right="352.17" top="496.97"><span x0="261.86" y0="496.97" x1="352.17" style="x0: 261.86; x1: 267.6; y0: 496.97; y1: 506.97; width: 5.74; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Roman;">There is deployable research capacity.There are regional laboratories responsible for conducting research, growing virus samples, curating them and sharing them, and creating animal models.</span></div><div left="414.93" right="516.44" top="403.87"><span x0="414.93" y0="403.87" x1="516.44" style="x0: 414.93; x1: 424.0; y0: 403.87; y1: 413.87; width: 9.07; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Roman;">Multi-sector discovery networks for medical countermeasures.</span></div><div left="414.93" right="547.94" top="350.67"><span x0="414.93" y0="350.67" x1="547.94" style="x0: 414.93; x1: 420.67; y0: 350.67; y1: 360.67; width: 5.74; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Roman;">There are global mechanisms to support technology transfers and R&amp;D capacity building. </span></div><div left="414.93" right="533.11" top="297.47"><span x0="414.93" y0="297.47" x1="533.11" style="x0: 414.93; x1: 420.67; y0: 297.47; y1: 307.47; width: 5.74; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Roman;">There are existing vaccine platforms or agents that have gone through phase 1, are ready, and are broadly cross-protective against a range of pathogens.</span></div><div left="414.93" right="548.44" top="204.37"><span x0="414.93" y0="204.37" x1="548.44" style="x0: 414.93; x1: 420.67; y0: 204.37; y1: 214.37; width: 5.74; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Roman;">There is sufficient deployable regional manufacturing capacity, measured as number of vaccine doses/diagnostic tests/therapeutics needed versus capacity to manufacture them.</span></div></body></html>